Shares of Caplin Point Laboratories surged 3.06% to Rs 2,038.00 during Wednesday’s session after the company announced a strategic acquisition through its Hong Kong-based subsidiary. Caplin Point Far East Limited has acquired 100% of Neoethicals Chile SpA, a pharmaceutical marketing and distribution firm operating in the Chilean market.
The acquisition was finalized on April 1, 2025, and was made at the face value of 1,000 Chilean Peso per share for a total of 3,000 shares, translating to approximately USD 3,000. The move positions Neoethicals as a wholly owned subsidiary of Caplin Point Far East and a step-down subsidiary of Caplin Point Laboratories.
Neoethicals Chile SpA, incorporated in 2015, has served as a distributor for Caplin Point’s products in Chile. With turnover rising to 278.56 million Chilean Pesos (approx. USD 295,000) in 2024, the acquisition aims to strengthen Caplin’s direct presence in the South American market and consolidate its front-end distribution network.
The stock saw positive investor sentiment as it touched an intraday high of Rs 2,111.20. Caplin Point now holds a market capitalization of Rs 154.77 billion with a P/E ratio of 30.18.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.